Indications
Indicated in preterm neonates for the prevention of bronchopulmonary dysplasia
Composition
- Active substance
- Caffeine citrate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Blectifor
- Active substance
- Caffeine citrate
- Therapeutic area
- Bronchopulmonary Dysplasia
- Marketing authorisation holder
- Viridian Pharma Ltd
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/004100
EMA designations
- Orphan medicine
- Yes
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No